Current Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study

Robert M Feldman,1 George A Cioffi,2 Jeffrey M Liebmann,3 Robert N Weinreb4 1The University of Texas Medical School Houston, TX, USA; 2Department of Ophthalmology, NewYork Presbyterian Hospital Columbia University Irving Medical Center, NY, New York, USA; 3Columbia University Medical Center, New Yor...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Feldman RM, Cioffi GA, Liebmann JM, Weinreb RN
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	open-angle glaucoma ocular hypertension cost-effectiveness clinician knowledge and attitudes focus group prostaglandin analogs Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/a8abaa93ba77470eb2e4b8cfa371a50e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a8abaa93ba77470eb2e4b8cfa371a50e
record_format	dspace
spelling	oai:doaj.org-article:a8abaa93ba77470eb2e4b8cfa371a50e2021-12-02T10:38:49ZCurrent Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study1177-5483https://doaj.org/article/a8abaa93ba77470eb2e4b8cfa371a50e2020-03-01T00:00:00Zhttps://www.dovepress.com/current-knowledge-and-attitudes-concerning-cost-effectiveness-in-glauc-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Robert M Feldman,1 George A Cioffi,2 Jeffrey M Liebmann,3 Robert N Weinreb4 1The University of Texas Medical School Houston, TX, USA; 2Department of Ophthalmology, NewYork Presbyterian Hospital Columbia University Irving Medical Center, NY, New York, USA; 3Columbia University Medical Center, New York, NY, USA; 4University of California San Diego, LaJolla, CA, USACorrespondence: Robert M FeldmanDepartment of Ophthalmology and Visual Science, The University of Texas Medical School at Houston, 6400 Fannin St., Ste 1800, Houston, TX 77030, USATel +1 713 559 5200Fax +1 713 795 0733Email Bleb@swbell.netBackground: Rising healthcare costs motivate continued cost-reduction efforts. To help lower costs associated with open-angle glaucoma (OAG), a prevalent, progressive disease with substantial direct and indirect costs, clinicians need to understand the cost-effectiveness of intraocular pressure (IOP)-lowering pharmacotherapies. There is little published information on clinicians’ knowledge and attitudes about cost-effectiveness in glaucoma treatment.Purpose: This pilot focus group study aimed to explore clinician attitudes and perspectives around the costs and cost drivers of glaucoma therapy; the implementation of cost-effectiveness decisions; the clinical utility of cost-effectiveness studies; and the cost-effectiveness of available treatments.Methods: Six US glaucoma specialists participated in two separate teleconferencing sessions (three participants each), managed by an independent, skilled moderator (also a glaucoma specialist) using a discussion guide. Participants reviewed recent publications (n=25) on health economics outcomes research in glaucoma prior to the sessions.Results: Participants demonstrated a clear understanding of the economic burden of glaucoma therapy and identified medications, diagnostics, office visits, and treatment changes as key cost drivers. They considered cost-effectiveness an appropriate component of treatment decision-making but identified the need for additional data to inform these decisions. Participants indicated that there were only a few recent studies on health economics outcomes in glaucoma which evaluate parameters important to patient care, such as quality of life and medication adherence, and that longitudinal data were scant. In addition to efficacy, participants felt patient adherence and side-effect profile should be included in economic evaluations of glaucoma pharmacotherapy. Recently approved medications were evaluated in this context.Conclusion: Clinicians deem treatment decisions based on cost-effectiveness data as clinically appropriate. Newer IOP-lowering therapies with potentially greater efficacy and favorable side-effect and adherence profiles may help optimize cost-effectiveness. Future studies should include: clinicians’ perspectives; lack of commercial bias; analysis of long-term outcomes/costs; more comprehensive parameters; real-world (including quality-of-life) data; and a robust Markov model.Keywords: open-angle glaucoma, ocular hypertension, cost-effectiveness, clinician knowledge and attitudes, focus group, prostaglandin analogsFeldman RMCioffi GALiebmann JMWeinreb RNDove Medical Pressarticleopen-angle glaucomaocular hypertensioncost-effectivenessclinician knowledge and attitudesfocus groupprostaglandin analogsOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 729-739 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	open-angle glaucoma ocular hypertension cost-effectiveness clinician knowledge and attitudes focus group prostaglandin analogs Ophthalmology RE1-994
spellingShingle	open-angle glaucoma ocular hypertension cost-effectiveness clinician knowledge and attitudes focus group prostaglandin analogs Ophthalmology RE1-994 Feldman RM Cioffi GA Liebmann JM Weinreb RN Current Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study
description	Robert M Feldman,1 George A Cioffi,2 Jeffrey M Liebmann,3 Robert N Weinreb4 1The University of Texas Medical School Houston, TX, USA; 2Department of Ophthalmology, NewYork Presbyterian Hospital Columbia University Irving Medical Center, NY, New York, USA; 3Columbia University Medical Center, New York, NY, USA; 4University of California San Diego, LaJolla, CA, USACorrespondence: Robert M FeldmanDepartment of Ophthalmology and Visual Science, The University of Texas Medical School at Houston, 6400 Fannin St., Ste 1800, Houston, TX 77030, USATel +1 713 559 5200Fax +1 713 795 0733Email Bleb@swbell.netBackground: Rising healthcare costs motivate continued cost-reduction efforts. To help lower costs associated with open-angle glaucoma (OAG), a prevalent, progressive disease with substantial direct and indirect costs, clinicians need to understand the cost-effectiveness of intraocular pressure (IOP)-lowering pharmacotherapies. There is little published information on clinicians’ knowledge and attitudes about cost-effectiveness in glaucoma treatment.Purpose: This pilot focus group study aimed to explore clinician attitudes and perspectives around the costs and cost drivers of glaucoma therapy; the implementation of cost-effectiveness decisions; the clinical utility of cost-effectiveness studies; and the cost-effectiveness of available treatments.Methods: Six US glaucoma specialists participated in two separate teleconferencing sessions (three participants each), managed by an independent, skilled moderator (also a glaucoma specialist) using a discussion guide. Participants reviewed recent publications (n=25) on health economics outcomes research in glaucoma prior to the sessions.Results: Participants demonstrated a clear understanding of the economic burden of glaucoma therapy and identified medications, diagnostics, office visits, and treatment changes as key cost drivers. They considered cost-effectiveness an appropriate component of treatment decision-making but identified the need for additional data to inform these decisions. Participants indicated that there were only a few recent studies on health economics outcomes in glaucoma which evaluate parameters important to patient care, such as quality of life and medication adherence, and that longitudinal data were scant. In addition to efficacy, participants felt patient adherence and side-effect profile should be included in economic evaluations of glaucoma pharmacotherapy. Recently approved medications were evaluated in this context.Conclusion: Clinicians deem treatment decisions based on cost-effectiveness data as clinically appropriate. Newer IOP-lowering therapies with potentially greater efficacy and favorable side-effect and adherence profiles may help optimize cost-effectiveness. Future studies should include: clinicians’ perspectives; lack of commercial bias; analysis of long-term outcomes/costs; more comprehensive parameters; real-world (including quality-of-life) data; and a robust Markov model.Keywords: open-angle glaucoma, ocular hypertension, cost-effectiveness, clinician knowledge and attitudes, focus group, prostaglandin analogs
format	article
author	Feldman RM Cioffi GA Liebmann JM Weinreb RN
author_facet	Feldman RM Cioffi GA Liebmann JM Weinreb RN
author_sort	Feldman RM
title	Current Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study
title_short	Current Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study
title_full	Current Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study
title_fullStr	Current Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study
title_full_unstemmed	Current Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study
title_sort	current knowledge and attitudes concerning cost-effectiveness in glaucoma pharmacotherapy: a glaucoma specialists focus group study
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/a8abaa93ba77470eb2e4b8cfa371a50e
work_keys_str_mv	AT feldmanrm currentknowledgeandattitudesconcerningcosteffectivenessinglaucomapharmacotherapyaglaucomaspecialistsfocusgroupstudy AT cioffiga currentknowledgeandattitudesconcerningcosteffectivenessinglaucomapharmacotherapyaglaucomaspecialistsfocusgroupstudy AT liebmannjm currentknowledgeandattitudesconcerningcosteffectivenessinglaucomapharmacotherapyaglaucomaspecialistsfocusgroupstudy AT weinrebrn currentknowledgeandattitudesconcerningcosteffectivenessinglaucomapharmacotherapyaglaucomaspecialistsfocusgroupstudy
_version_	1718396901962809344

Current Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study

Ejemplares similares